Compare Ally Financial Inc (ALLY) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ally Financial Inc vs IDEXX Laboratories, Inc. — how do they compare? Ally Financial Inc trades at $43.76 (market cap $13.37B), while IDEXX Laboratories, Inc. trades at $571.83 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.5× Ally Financial Inc's market cap, and Ally Financial Inc pays a 2.73% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| ALLY | IDXX | |
|---|---|---|
Market Cap | $13.37B | $46.22B |
Sector | Financials | Health |
52-Week High | $47.25 | $766.68 |
52-Week Low | $35.96 | $526.44 |
Dividend Yield | 2.73% | — |
Enterprise Value | — | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ally Financial (ALLY) trades at $43.81, showing minimal daily movement. The stock exhibits a bearish technical signal with recent earnings missing estimates in Q2 2026, though revenue grew 10% year-over-year. Valuation metrics appear attractive with a P/E of 10.34 and P/B below 1. Analyst consensus remains strongly bullish with a $54.40 price target, but insider selling and mixed technical indicators suggest near-term caution.
The outlook for ALLY hinges on execution amid macroeconomic pressures. Upside potential exists from solid loan growth and digital banking strength, but risks include rising provisions, competitive pressures, and interest rate sensitivity. Earnings growth in upcoming quarters is critical for sustaining investor confidence and driving the stock toward analyst targets.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
